Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
Trump's threat, posted on Twitter, comes amid rising international tensions in the Middle East as the U.S. has dispatched a carrier strike group and bomber task force to the...Politicsread more
Stocks in Asia were mostly higher on Monday amid rising tensions between the U.S. and China.Asia Marketsread more
Current geopolitical tensions are making it harder and harder for oil-producing nations to make decisions that will help stabilize crude prices, Russian Energy Minister...Oilread more
Russian Energy Minister Alexander Novak said there were different options available for OPEC and its oil-producing allies in the second half of 2019, including a possible...Oilread more
Huawei is developing its own operating system for smartphones and laptops, but the company says it would only be used in "extenuating circumstances."Technologyread more
The Australian Electoral Commission (AEC) on Monday said Morrison's coalition has won 75 seats in Australia's parliament, one seat short of a 76-seat majority.Electionsread more
U.S. President Donald Trump said his tariffs on Chinese goods are causing companies to move production out of China to Vietnam and other countries in Asia, and added that any...World Politicsread more
SoftBank founder Masayoshi Son speaks in futuristic terms about his company, but the success of his late-stage VC fund is still unknown.Technologyread more
Reports of Tesla vehicles spontaneously catching fire could make customers wary of EVs just as the industry ramps up production plans.Autosread more
Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Several of the world's biggest pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients in medical research.
GlaxoSmithKline and AstraZeneca, the two biggest UK drugs groups, will team up with rivals, including Roche of Switzerland and AbbVie and Biogen of the US, to mine information from a government project to decode the genomes of 100,000 patients with cancer and rare diseases.
The 10-strong consortium will carry out a year-long trial aimed at bringing industry expertise to the project and finding ways to use the genetic data to aid discovery of more personalised medicines.
So far, about 3,000 genomes have been sequenced during the project's pilot stage, with a target to reach 100,000 by 2017, creating what would be the world's largest database of the DNA code in human cells.
This should help researchers discover genetic mutations linked to certain diseases, which could in turn aid development of genetically targeted treatments.
Sir John Chisholm, executive chairman of Genomics England, the state-owned company set up to run the project, said industry participation was crucial if the data were to produce benefits for patients.
He made clear that safeguards were in place to ensure patient data were made anonymous.
Last year, the government was forced to postpone a plan to make patient records from hospitals and family doctors available to researchers through a scheme called Care. Data after a backlash from privacy campaigners.
The 100,000 Genomes Project is different in that it involves people who have volunteered to take part. Sir John said most were keen for their data to be used in research that might lead to a cure.
Nonetheless, he said, drug companies would only be allowed access to the data in a tightly controlled way, describing the project as "more like a reading library than a lending library".
Martin Mackay, head of research and development at Alexion, a US biotech company taking part in the consortium, said the scheme had the potential to "accelerate the understanding of the genetic basis of rare diseases and ultimately lead to improved diagnostics and treatments".
The other members of the alliance — called the Gene Consortium — are UCB of Belgium, Takeda of Japan, and Dimension Therapeutics and Helomics of the US.
Genomics England will also announce partnerships with scientists and academic institutions in another move to make its database available to researchers.
The 100,000 Genomes Project is part of efforts by the government to use the NHS and its wealth of medical data to attract international medical research and life sciences investment.
Sir John is a veteran of the software and engineering industries who oversaw the privatisation of Qinetiq, the government's defence technology service business.
"I spent a large amount of my working life in the microelectronic revolution which [changed] the 20th century," he told the Financial Times. "Genetics [is] going to change the world in the 21st century."
Genomics England could play an important role, he added, in the shift towards more personalised medicines to tackle the genetic defects of individual patients.
"We will look back on how we used to pour pills down our necks as being not much different to how we look back on bleeding someone who has a fever."
Another large genomic database has been built by 23andMe, a Google-backed Californian company that sells $99 DNA testing kits.
But the 100,000 Genomes project promises a much richer resource because, unlike 23andMe, it is sequencing whole genomes rather than just fragments.